SK bioscience Co. announced on Thursday that it has partnered with Vaxxas, an Australian biotechnology company, to develop a patch-type typhoid vaccine. The two-year project, which is being funded by the global charitable foundation Wellcome, will receive $3.67 million to launch the first clinical trial.
SK bioscience will provide the antigen for its SKYTyphoid conjugate vaccine to Vaxxas, who will use its high-density microarray patch (HD-MAP) platform technology to create the new vaccine-delivery device. HD-MAP is designed to administer the vaccine directly to the skin’s immune cells, making it more immunogenic than traditional needle and syringe methods.
The patch-type vaccine also reduces the cost and complexity of cold-chain distribution and storage, which can make it more accessible in lower- and middle-income countries, SK bioscience said.
The corporate logo of SK bioscience Co. (Yonhap)
brk@yna.co.kr
(END)